Heparin-induced coagulopathy.
Intravenous heparin, at doses of 3.0 U./gm of body weight, produced an intravascular coagulopathy in rats which was manifested by intestinal tract hemorrhage, a reduction in plasma fibrinogen concentration, a rise in fibrinogen-fibrin degradation products, and the absence of a rise in platelet count noted in the control animals. This coagulopathy could not be produced by conventional anticoagulant doses of heparin or the injection of large doses of heparin in the presence of protamine sulfate. Specific studies excluded hypoxemia, metabolic acidosis, and endotoxemia as possible etiologic factors. The coagulation abnormalities observed in this study differ from those produced by injection of other polyanionic substances but their precise pathogenesis is still uncertain.
D000818:Animals; D001772:Blood Cell Count; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001792:Blood Platelets; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000473:pathology; D006493:Heparin / Q000494:pharmacology; D008297:Male; D011479:Protamines / Q000494:pharmacology; D051381:Rats
D004731:Endotoxins; D005338:Fibrin Fibrinogen Degradation Products; D011479:Protamines; D005340:Fibrinogen; D006493:Heparin